Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Kadmon Holdings Inc's Business Segments
Kadmon Holdings Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 15
Regions Reported
-
Kadmon Holdings Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product Sales83.1%
- Rezurock Product Sales83.1%
- License and Other Revenue16.9%
- License Revenue13.6%
- Other Revenue3.3%
- Other Product Sales0.1%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product Sales | $ 12 | 83.1% |
| Rezurock Product Sales | $ 12 | 83.1% |
| License and Other Revenue | $ 2 | 16.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
3 more categories available
Sign in to unlock the full Kadmon Holdings Inc dataset.
Description of Kadmon Holdings Inc
Kadmon Holdings, Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies for unmet medical needs. The company was founded in 2010 and is headquartered in New York City, New York.
Kadmon's primary area of focus is immunology and oncology, with a portfolio of potential therapies targeting various diseases, including autoimmune and inflammatory disorders, fibrosis, and solid and liquid tumors. The company utilizes a variety of approaches, including small molecules, biologics, and gene therapies, to develop its pipeline of therapeutic candidates.
One of Kadmon's lead candidates is belumosudil (KD025), an orally available selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). Belumosudil is being developed as a potential treatment for chronic graft-versus-host disease (cGVHD), a debilitating complication that can occur after hematopoietic stem cell transplantation. The drug has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) and is currently in late-stage clinical development.
In addition to belumosudil, Kadmon has a number of other product candidates in its pipeline. These include KD033, a monoclonal antibody being developed for the treatment of fibrotic disease, and KD045, a potential treatment for various autoimmune disorders.
Kadmon also operates a commercial business segment, through which it markets and sells certain generic pharmaceutical products. This segment generates revenue for the company and helps to fund its research and development efforts.
The company has established partnerships and collaborations with other biopharmaceutical companies and academic institutions to further enhance its drug discovery and development capabilities. Kadmon also actively pursues opportunities for in-licensing or acquiring new product candidates to expand its pipeline.
As a publicly traded company, Kadmon Holdings, Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol KDMN. The company has a diverse team of experienced scientists, researchers, and professionals dedicated to advancing their mission of developing innovative therapies to improve the lives of patients with serious medical conditions.
Kadmon's primary area of focus is immunology and oncology, with a portfolio of potential therapies targeting various diseases, including autoimmune and inflammatory disorders, fibrosis, and solid and liquid tumors. The company utilizes a variety of approaches, including small molecules, biologics, and gene therapies, to develop its pipeline of therapeutic candidates.
One of Kadmon's lead candidates is belumosudil (KD025), an orally available selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). Belumosudil is being developed as a potential treatment for chronic graft-versus-host disease (cGVHD), a debilitating complication that can occur after hematopoietic stem cell transplantation. The drug has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) and is currently in late-stage clinical development.
In addition to belumosudil, Kadmon has a number of other product candidates in its pipeline. These include KD033, a monoclonal antibody being developed for the treatment of fibrotic disease, and KD045, a potential treatment for various autoimmune disorders.
Kadmon also operates a commercial business segment, through which it markets and sells certain generic pharmaceutical products. This segment generates revenue for the company and helps to fund its research and development efforts.
The company has established partnerships and collaborations with other biopharmaceutical companies and academic institutions to further enhance its drug discovery and development capabilities. Kadmon also actively pursues opportunities for in-licensing or acquiring new product candidates to expand its pipeline.
As a publicly traded company, Kadmon Holdings, Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol KDMN. The company has a diverse team of experienced scientists, researchers, and professionals dedicated to advancing their mission of developing innovative therapies to improve the lives of patients with serious medical conditions.
Kadmon Holdings, Inc. based in the United States, focuses on the development and commercialization of innovative therapies for patients with unmet medical needs, particularly in the areas of immunology, nephrology, and oncology. The company operates in various segments, each dedicated to specific therapeutic areas and product lines, which primarily include the following:
Segments
1. Immunology
- In this segment, Kadmon is focused on developing therapies that aim to modulate the immune response. The goal is to provide effective treatments for autoimmune diseases and conditions where the immune system is dysregulated.
2. Nephrology
- Kadmon is involved in creating treatments for kidney-related conditions. This segment aims to address serious renal diseases and other complications affecting kidney function, with a robust pipeline targeting various indications.
3. Oncology
- The oncology segment is dedicated to the development of therapies for various types of cancers. This includes targeted therapies and potential immunotherapies that leverage the body’s immune system to fight cancer cells.
Products
Kadmon has developed several key products aimed at treating serious diseases:
1. Rezurock (belumosudil)
- Rezurock is a revolutionary therapy designed for patients with chronic graft-versus-host disease (cGVHD) after failure of other therapies. It works by inhibiting key immune processes involved in the pathology of cGVHD, offering a new treatment alternative for patients who have limited options.
2. KD025 (belumosudil)
- KD025 is a potent, selective, oral inhibitor of Rho-associated coiled-coil-containing protein kinase (ROCK), primarily investigated in cGVHD and other immunology-related indications.
3. Pipeline Products
- Kadmon has a robust pipeline of investigational products targeting various conditions in immunology, nephrology, and oncology. These candidates include therapies at different stages of clinical development and target diseases where current treatment options are limited or suboptimal.
Services
In addition to its pharmaceutical products, Kadmon may also provide:
1. Clinical Trial Management
- This includes the design and conduct of clinical trials to test the efficacy and safety of new treatments, ensuring compliance with regulatory standards.
2. Regulatory Affairs Consultation
- Advising on regulatory submissions and strategies to ensure that products meet the standards set by health authorities for approval and commercialization.
3. Patient Support Programs
- Kadmon may offer services designed to assist patients in managing their diseases, including educational resources, access support, and consultation with healthcare professionals to optimize treatment outcomes.
4. Collaborative Partnerships
- Engaging in partnerships with other biotechnology companies, academic institutions, and research organizations to enhance research capabilities and broaden the reach of its therapeutic products.
Research and Development
Research and development play a critical role in Kadmon’s operations, with a focus on innovating new treatment modalities through:
- In-house drug discovery
- Clinical research collaboration
- Leveraging cutting-edge technologies to enhance drug efficacy and patient outcomes
Additional Commitments
Kadmon Holdings also emphasizes its commitment to:
- Ethical Standards: Ensuring high ethical standards in clinical trials and product development.
- Patient-Centric Approach: Focused on understanding and addressing the needs of patients suffering from serious medical conditions.
- Continued Innovation: Investing in technology and research to develop next-generation treatments that can significantly improve patient care.
Kadmon Holdings, Inc. continues to evolve, aiming to position itself as a leader in the biopharmaceutical industry, dedicated to advancing medical science and improving patient lives through innovative therapies.
Segments
1. Immunology
- In this segment, Kadmon is focused on developing therapies that aim to modulate the immune response. The goal is to provide effective treatments for autoimmune diseases and conditions where the immune system is dysregulated.
2. Nephrology
- Kadmon is involved in creating treatments for kidney-related conditions. This segment aims to address serious renal diseases and other complications affecting kidney function, with a robust pipeline targeting various indications.
3. Oncology
- The oncology segment is dedicated to the development of therapies for various types of cancers. This includes targeted therapies and potential immunotherapies that leverage the body’s immune system to fight cancer cells.
Products
Kadmon has developed several key products aimed at treating serious diseases:
1. Rezurock (belumosudil)
- Rezurock is a revolutionary therapy designed for patients with chronic graft-versus-host disease (cGVHD) after failure of other therapies. It works by inhibiting key immune processes involved in the pathology of cGVHD, offering a new treatment alternative for patients who have limited options.
2. KD025 (belumosudil)
- KD025 is a potent, selective, oral inhibitor of Rho-associated coiled-coil-containing protein kinase (ROCK), primarily investigated in cGVHD and other immunology-related indications.
3. Pipeline Products
- Kadmon has a robust pipeline of investigational products targeting various conditions in immunology, nephrology, and oncology. These candidates include therapies at different stages of clinical development and target diseases where current treatment options are limited or suboptimal.
Services
In addition to its pharmaceutical products, Kadmon may also provide:
1. Clinical Trial Management
- This includes the design and conduct of clinical trials to test the efficacy and safety of new treatments, ensuring compliance with regulatory standards.
2. Regulatory Affairs Consultation
- Advising on regulatory submissions and strategies to ensure that products meet the standards set by health authorities for approval and commercialization.
3. Patient Support Programs
- Kadmon may offer services designed to assist patients in managing their diseases, including educational resources, access support, and consultation with healthcare professionals to optimize treatment outcomes.
4. Collaborative Partnerships
- Engaging in partnerships with other biotechnology companies, academic institutions, and research organizations to enhance research capabilities and broaden the reach of its therapeutic products.
Research and Development
Research and development play a critical role in Kadmon’s operations, with a focus on innovating new treatment modalities through:
- In-house drug discovery
- Clinical research collaboration
- Leveraging cutting-edge technologies to enhance drug efficacy and patient outcomes
Additional Commitments
Kadmon Holdings also emphasizes its commitment to:
- Ethical Standards: Ensuring high ethical standards in clinical trials and product development.
- Patient-Centric Approach: Focused on understanding and addressing the needs of patients suffering from serious medical conditions.
- Continued Innovation: Investing in technology and research to develop next-generation treatments that can significantly improve patient care.
Kadmon Holdings, Inc. continues to evolve, aiming to position itself as a leader in the biopharmaceutical industry, dedicated to advancing medical science and improving patient lives through innovative therapies.